TMDX (TransMedics Group) stock outlook for 2026. A qualitative deep dive into how the OCS perfusion device replaces the ice cooler, the equipment-plus-consumables-plus-aviation model, the organ utilization thesis, and the valuation, execution, regulatory, and short-seller risks.
Hologic (NASDAQ: HOLX) stock analysis for 2026: the Panther molecular installed base and assay pull-through, 3D Genius mammography and recurring service revenue, the post-COVID normalization to a clean organic-growth base, the women's-health moat, tuck-in M&A and buybacks, plus competitive risk from Roche, BD, GE HealthCare and Siemens.
Masimo (MASI) 2026 stock outlook. A deep look at the SET pulse oximetry moat, the razor-and-blade sensor model, the Sound United misstep, the Politan activist campaign and governance reset, and the Apple Watch ITC patent win.
Insulet (PODD) stock analysis for 2026: Omnipod 5 AID momentum, type-2 diabetes expansion, pharmacy-channel growth, GLP-1 overhang debate, and competitive risks from Tandem and Medtronic.
A qualitative deep-dive into The Cooper Companies (COO) stock outlook for 2026 — CooperVision's specialty lens mix shift, MiSight myopia management, CooperSurgical fertility tailwinds, and key risks to watch.
Dexcom (DXCM) stock analysis 2026: $4.82B TTM revenue up 16.2%, EPS +75.5% to $2.34, P/E 30.8x, GLP-1 drug interaction with CGM adoption, Stelo OTC launch, FreeStyle Libre competition, and analyst consensus Strong Buy with $81.64 target.